Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.45 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.38 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7334784 | 0.98 | IDO1 (0.44) | TAAR1IDO1ALDH1A1GRIN2BMAOB | |
| SCHEMBL5068041 | 0.78 | TAAR1 (0.66) | TAAR1IDO1GRIN2BGRIN1LMNA | |
| Bromide SCHEMBL4621302 | 0.78 | BACE1 (0.38) | TAAR1GRIN2BGRIN1NOS2 | |
| Hydrochloric Acid SCHEMBL4797248 | 0.77 | TAAR1 (0.64) | TAAR1IDO1GRIN2BGRIN1LMNA | |
| Hydrochloric Acid SCHEMBL3396072 | 0.77 | IDO1 (0.47) | TAAR1IDO1ALDH1A1GRIN2BMAOB | |
| Bromide SCHEMBL4622918 | 0.73 | GRIN2B (0.61) | TAAR1GRIN2BGRIN1 | |
| SCHEMBL1230273 | 0.71 | NOS2 (0.67) | GRIN2BGRIN1NOS2 | |
| SCHEMBL423414 | 0.70 | TAAR1 (0.50) | TAAR1IDO1ALDH1A1AOC3LMNA | |
| SCHEMBL27604357 | 0.69 | TAAR1 (0.50) | TAAR1IDO1ALDH1A1MAOBAOC3 | |
| Hydrochloric Acid SCHEMBL4003818 | 0.69 | NOS2 (0.64) | GRIN2BGRIN1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754768-B2 | Methods and compositions for modulating alpha adrenergic receptor activity | ALLERGAN, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20080132576-A1 | METHODS AND COMPOSITIONS FOR MODULATING ALPHA ADRENERGIC RECEPTOR ACTIVITY | ALLERGAN, INC. | 2008-06-05 | — | — | US | disclosed |
| US-7335803-B2 | Methods and compositions for modulating alpha adrenergic receptor activity | ALLERGAN, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| EP-1280524-B1 | METHODS AND COMPOSITIONS FOR MODULATING ALPHA ADRENERGIC RECEPTOR ACTIVITY | ALLERGAN INC (US) | 2006-04-05 | — | — | EP | disclosed |
| EP-1280525-B1 | METHODS AND COMPOSITIONS FOR MODULATING ALPHA ADRENERGIC RECEPTOR ACTIVITY | ALLERGAN INC (US) | 2005-02-09 | — | — | EP | disclosed |
| US-20030092766-A1 | Methods and compositions for modulating alpha adrenergic receptor activity | ALLERGAN SALES, INC. | 2003-05-15 | — | — | US | disclosed |
| WO-2003035178-A1 | METHODS AND COMPOSITIONS FOR MODULATING ALPHA ADRENERGIC RECEPTOR ACTIVITY | ALLERGAN, INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| US-6545182-B2 | For pain therapy | ALLERGAN SALES, INC. | 2003-04-08 | — | — | US | disclosed |
| EP-1280525-A2 | METHODS AND COMPOSITIONS FOR MODULATING ALPHA ADRENERGIC RECEPTOR ACTIVITY | Allergan, Inc. (US) | 2003-02-05 | — | — | EP | disclosed |
| EP-1280524-A2 | METHODS AND COMPOSITIONS FOR MODULATING ALPHA ADRENERGIC RECEPTOR ACTIVITY | Allergan, Inc. (US) | 2003-02-05 | — | — | EP | disclosed |
| US-20020058839-A1 | Methods and compositions for modulating alpha adrenergic receptor activity | ALLERGAN SALES, INC. | 2002-05-16 | — | — | US | disclosed |
| US-6313172-B1 | ADMINISTERING HYDROXYETHYLTHIOUREA DERIVATIVE FOR THERAPY OF PAIN IN MAMMAL | ALLERGAN SALES, INC. | 2001-11-06 | — | — | US | disclosed |
| WO-2001078703-A2 | METHODS AND COMPOSITIONS FOR MODULATING ALPHA ADRENERGIC RECEPTOR ACTIVITY | ALLERGAN, INC. (US) | 2001-10-25 | — | — | WO | disclosed |
| WO-2001078702-A2 | METHODS AND COMPOSITIONS FOR MODULATING ALPHA ADRENERGIC RECEPTOR ACTIVITY | ALLERGAN, INC. (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058839-A1 | Methods and compositions for modulating alpha adrenergic receptor activity | ADRB2, ADRA2A, ADRA2C | TAAR1 235/4885IDO1 3608/4885ALDH1A1 1420/4885 |
| US-20080132576-A1 | METHODS AND COMPOSITIONS FOR MODULATING ALPHA ADRENERGIC RECEPTOR ACTIVITY | ADRB2, ADRA2A, ADRB1 | TAAR1 437/4885IDO1 3481/4885ALDH1A1 1656/4885 |
| US-20030092766-A1 | Methods and compositions for modulating alpha adrenergic receptor activity | ADRB2, ADRA2A, ADRB1 | TAAR1 437/4885IDO1 3481/4885ALDH1A1 1656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.